Sign Out
Severe Eosinophilic Asthma: NUCALA is indicated as an add-on maintenance treatment for patients aged 12 years old and older with severe eosinophilic asthma who: have at least two exacerbations in the preceding 12 months on current standard of care (high doses of inhaled corticosteroids plus additional maintenance treatment) and/or requirement for treatment with systemic corticosteroids, and have a blood eosinophil count of ≥ 150 cells/μL (0.15 GI/L) at initiation of treatment with NUCALA OR ≥ 300 cells/μL (0.3 GI/L) in the past 12 months.
NUCALA is not indicated for other eosinophilic conditions or for relief of acute bronchospasm or status asthmaticus (see Precautions).
